

REMARKS

Claims 1, 62-77, and new claims 78-90 are pending upon entry of the above-made amendments. Claims 2-61 are canceled, without prejudice. New claims 78-90 are added in the present amendment in order to particularly point out and distinctly claim Applicant's invention. New claims 78-90 are completely supported in the specification, and no new matter has been introduced.

More specifically, support for new claim 78, is found at page 10, lines 11-22, at page 14, lines 27-32, and at page 36, lines 25-27 (with respect to hsp association with peptides and proteins); at page 14, lines 14-17 (as corrected in the Preliminary Amendment filed August 12, 2003); at page 25, lines 1-17; and at page 60, lines 5-25, including the text inserted by Preliminary Amendment filed August 12, 2003 (with respect to the purification of hsp complexes on an ADP column).

Support for new claim 79 is found at page 16, lines 5-24.

Support for new claim 80 is found at page 15, lines 29-31, and at page 16, lines 5-24, including the text and Table 1 inserted by the Preliminary Amendment filed August 12, 2003.

Support for new claim 81 is found at page 16, lines 5-24. That is, since Applicant has positively recited particular hsp families useful in the invention, Applicant may explicitly exclude one such family from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

Support for new claim 82 is found at page 15, lines 28-31, and at page 16, lines 5-24, including the text and Table 1 inserted by the Preliminary Amendment filed August 12, 2003. That is, since Applicant has positively recited particular hsp species useful in the invention, Applicant may explicitly exclude one such species from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

Support for new claim 83 is found at page 16, lines 5-24, and at page 36, lines 25-32, including the text inserted by the Preliminary Amendment filed August 12, 2003

Support for new claim 84, is found at page 16, lines 5-24.

Support for new claim 85, is found at page 15, lines 29-31, and at page 16, lines 5-24, including the text and Table 1 inserted by the Preliminary Amendment filed August 12, 2003.

With respect to new claim 86, support for “wherein the hsp is not an hsp70 family member” is found in the specification as filed at page 16 lines 5-24. That is, since Applicant has positively recited particular hsp families useful in the invention, Applicant may explicitly exclude one such family from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

With respect to new claim 87, support for “wherein the hsp is not hsp70” is found in the specification at page 15, lines 29-31, at page 16 lines 5-24, including the text and Table 1 inserted by the Preliminary Amendment filed August 12, 2003. That is, since Applicant has positively recited particular hsp species useful in the invention, Applicant may explicitly exclude one such species from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

With respect to new claim 88, support for: “a purified ADP-heat shock protein-peptide complex” is found at page 16 lines 5-24; at page 36 lines 25-32, including text inserted by the Preliminary Amendment filed August 12, 2003; at page 60, lines 5-25, including text inserted by the Preliminary Amendment filed August 12, 2003; additional support for the term “purified” is found in the specification at page 23, lines 8-18, at page 23 line 20, to page 29 line 14, in conjunction with page 36 lines 5-11 and lines 18-21.

With respect to new claim 89, support for “wherein the hsp is not an hsp70 family member” is found in the specification as filed at page 16 lines 5-24. That is, since Applicant has positively recited particular hsp families useful in the invention, Applicant may explicitly exclude one such family from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

With respect to new claim 90, support for “wherein the hsp is not hsp70” is found in the specification as filed at page 15, lines 29-31, and at page 16 lines 5-24, including the text and Table 1 inserted by the Preliminary Amendment filed August 12, 2003. That is, since Applicant has positively recited particular hsp species useful in the invention, Applicant may explicitly exclude one such species from the scope of a claim (*In re Johnson* 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977); *also see* MPEP 2173.05(i)).

Notification to the Examiner

Pursuant to Former Rule 37 C.F.R. § 1.607(c)

Applicant hereby notifies the Examiner that new claims 78-90, presented herein, particularly claims 82, 86, and 90, correspond exactly or substantially to claims 1-3, respectively, of U.S. Patent No. 6,713,608 B2 to Wallen *et al.* ("the '608 patent"), which issued March 30, 2004, and is entitled "Purified Heat Shock Protein Complexes."

The instant application, filed on August 12, 2003, claims the benefit under 35 U.S.C. § 120 of Application Serial No. 09/090,754 ("the '754 application"), filed June 4, 1998, and of Application Serial No. 08/527,391 ("the '391 application") filed September 13, 1995, which issued November 17, 1998, as U.S. Patent No. 5,837,251 ("the '251 patent").

Applicant also hereby notifies the Examiner that Applicant's parent '754 application was involved in Interference No. 104,761. Interference No. 104,761 was initially declared October 12, 2001, between Applicant's parent '754 application and U.S. Patent No. 6,747,332 to Wallen *et al.*, and then redeclared February 7, 2002, to add U.S. Patent No. 6,066,716 to Wallen *et al.* ("the '716 patent"). Interference 104,761 was redeclared a second time on October 24, 2003 to add U.S. Patent No. 6,433,141 to Wallen *et al.* ("the '141 patent"). A copy of the Notice Redecaring Interference 104,761 is attached hereto as Exhibit B.

The '608 patent, which issued March 30, 2004 from Application Serial No. 10/176,418 ("the '418 application") filed June 20, 2002 (after Interference 104,761 had been declared), was filed as a division of Application Serial No. 09/534,381 ("the '381 application") filed March 24, 2000 and issued as the '141 patent on August 13, 2002. The '381 application was filed as a division of Application Serial No. 08/934,139 ("the '139 application"), filed September 19, 1997, and issued May 23, 2000, as U.S. Patent No. 6,066,716 ("the '716 patent"), which is a division of Application Serial No. 08/717,239 ("the '239 application"), filed September 20, 1996, and issued May 5, 1998, as U.S. Patent No. 5,747,332 ("the '332 patent"). Again, as noted above the '332 patent, the '716 patent, and the '716 patent were involved in Interference 104,761 with Applicant's parent '054 application.

In connection with Interference 104,761, the Board of Patent Appeals and Interferences issued their Decision on Reconsideration and Judgment on October 24, 2003

("Decision"; a copy of that paper is attached hereto as Exhibit C). In this Decision, Fordham (assignee of the above-captioned application as well as the parent ('754) and grandparent ('391) applications thereof), was awarded priority of invention with respect to the three Counts of Interference 104,761. Accordingly, the Board ordered that the University of New Mexico (Assignee of U.S. Patent 5,747,332, U.S. Patent 6,066,716 and U.S. Patent No. 6,433,141) was not entitled to: (a) a patent containing claims 1, 3-5, and 7-12 UNM's 5,747,332 patent, corresponding to Count 1; (b) a patent containing claims 13, 15-17, and 19-23 of UNM's 5,747,332 patent, corresponding to Count 4; and (c) a patent containing claims 13-30 of UNM's U.S. Patent No. 6,066,716 or claims 1-18 of UNM's U.S. Patent No. 6,433,141 patent, which correspond to Count 3.

Despite the above, the "'608 patent" issued on March 30, 2004 to Wallen *et al.* with a total of three claims, each of which is an independent claim. A copy of the '608 patent is attached as Exhibit A.

Applicant will file a Request for an Interference Under 37 C.F.R. §41.202(a) between Applicant's pending U.S. patent application Serial No. 09/090,754 and U.S. Patent No. 6,713,608 B2 of Wallen *et al.* In addition to that Request, in an abundance of caution, Applicant is filing the present amendment before the one-year anniversary of the issuance of the '608 patent of Wallen *et al.* in order to avoid a 35 U.S.C. § 135(b) issue.

CONCLUSION

Applicant respectfully requests that the amendments and remarks be entered and made of record in the instant application. An early allowance is earnestly requested.

Respectfully submitted,

Date March 29, 2005

Samuel B. Abrams 30,605
Samuel B. Abrams (Reg. No.)

By: Michael J. Ryan 41,283
Michael J. Ryan (Reg. No.)

Jones Day
222 East 41st Street
New York, New York 10017-6702
(212) 326-9028

Enclosures

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Patent Interference No. 104,761

UNIVERSITY OF NEW MEXICO
(5,747,332, 6,066,716, and 6,433,141),

Junior Party,

v.

FORDHAM UNIVERSITY
(09/090,754),

Senior Party.

NOTICE REDECLARING INTERFERENCE

A. Redeclaration of interference

The interference is redeclared (35 U.S.C. 135(a)) between the captioned parties. Details of the application, patents, counts, and claims designated as corresponding to the counts appear under headings E and F of this NOTICE.

B. Administrative patent judge assigned to administer the interference

The interference has been assigned to Administrative Patent Judge Richard Torczon. 37 CFR § 1.610.

C. Standing order

The Trial Section STANDING ORDER (Paper 2) continues to apply to this interference.

D. Discussion

The following enumerated findings are supported by at least a preponderance of the evidence.

- [1] Fordham moves (Paper 97) to add UNM's 6,433,141 patent to this interference or, in the alternative, to add claims to its own involved application and then have a second interference declared.
- [2] UNM opposes this motion (Paper 101).
- [3] Fordham has replied (Paper 106).
- [4] According to Fordham, its claims 68, 69, 71-75, and 82-88, which correspond to count 3, claim the same patentable invention as claims 1-14 of UNM's 141 patent.

The independent claims of the 141 patent, claims 1, 7, and 10 are [1040 at 5-6]:

1. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein comprises hsp90.

7. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein comprises gp96.

13. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein comprises grp94.

- [5] All of the heat shock proteins in UNM 141 claims 1, 7, and 3 are hsp90 family members [1040 at 4:1-2].
- [6] Count 3 is "The ADP-heat shock protein-peptide complex of UNM 716 claims 13, 19, or 25."
- [7] UNM 716 claims 13, 19, and 25 are:
 - 13. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein is selected from the group consisting of DnaK proteins from prokaryotes.

19. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein is selected from the group consisting of Ssa, Ssb, and Ssc from yeast.

25. A purified ADP-heat shock protein-peptide complex wherein said heat shock protein is selected from the group consisting of Grp75 and Grp78(Bip) from eukaryotes.

- [8] All of the heat shock proteins in UNM 716 claims 13, 19, and 25 are members of the hsp70 family [1008 at 3:62-64].

Fordham presents the same problem in its motion to add the 141 patent claims that it presented in its preliminary motion 4: Given ADP-[hsp70 family member]-peptide complexes, what would be the motivation to substitute an hsp90 family member for the hsp70 family member?

- [9] The Blachere article¹ [1018] provides a motivation to use hsp70, hsp90, or gp96 to chaperone and present antigenic tumor proteins.
- [10] This teaching would have provided the motivation, given knowledge of ADP-[hsp70 family member]-peptide complexes, to make ADP-gp96-peptide complexes or ADP-hsp90-peptide complexes.
- [11] A person having ordinary skill in the art would have known that gp96 and grp94 are essentially the same protein (Paper 97 at 4, Facts 5 & 6, admitted at Paper 101 at 1).
- [12] Fordham has presented numerous facts about actions taken by the examiner and UNM in the prosecution history of the 141 patent and related UNM applications, some of which support the conclusion that ADP-[hsp70 family member]-peptide complexes and

¹ N.E. Blachere et al., "Heat Shock Protein Vaccines Against Cancer", 14 J. Immunol. 352 (1993). Fordham's named inventor, Pramod K. Srivastava, is a co-author.

ADP-[hsp90 family member]-peptide complexes are the same invention and others which do not.

The prosecution history is so equivocal that very little weight can be accorded to it. Cf. Omega Engineering, Inc. v. Raytek Corp., 334 F.3d 1314, 1331, 67 USPQ2d 1321, 1333 (Fed. Cir. 2003) (cautioning against reading much into ambiguous prosecution history).

- [13] UNM's dependent 141 claims parallel each other and parallel Fordham's substantially copied claims for ADP-hsp70-peptide complexes as follows:

UNM 141 independent claim			Added limitations	Fordham claim	Added limitations
1	7	13		68	
2	8	14	combination not naturally occurring	71	made in vitro
3	9	15	hsp & peptide from same individual	72	hsp & peptide from same individual
4	10	16	hsp & peptide from different individuals	73	hsp & peptide from different individuals
5	11	17	hsp & peptide from different organisms	74	hsp & peptide from different organisms
6	12	18	hsp & peptide from different species	75	hsp & peptide from different species

- [14] UNM notes the added limitations in the dependent claims but provides no reason why these claims are patentably distinct from Fordham's claims corresponding to count 3 other than its arguments for the independent claims.

Since Fordham has established that UNM 141 claims 1-8 define the same patentable invention as claims already corresponding to count 3, Fordham's request for an exercise of discretion to add UNM's 141 patent to the interference with claims 1-18 corresponding to count 3 is GRANTED. Consequently, Fordham's suggestion that another interference be declared is DISMISSED as moot.

Fordham requested a hearing if its motion to add was likely to be denied (Paper 105). UNM did not request a hearing on the motion. Since the motion is GRANTED to the extent that all claims of the UNM 141 patent have been added to correspond to Count 3, Fordham's request for a hearing is DENIED as moot.

E. The parties to this interference

Junior Party

Inventors: Erik S. Wallen, Jan Roigas, and Pope L. Moseley

Patent: 5,747,332, issued 5 May 1998 [332]
(08/717,239, filed 20 September 1996)

Title: Methods for purifying and synthesizing heat shock protein complexes

Accorded None
benefit:

Patent: 6,066,716, issued 23 May 2000 [716]
(08/934,139, filed 19 September 1997)

Title: Purified heat shock protein complexes

Accorded 08/717,239 (above)
benefit:

Patent: 6,433,141, issued 13 August 2002 [141]
(09/534,381, filed 24 May 2000)

Title: Purified heat shock protein complexes

Accorded 08/717,239 (above)
benefit: 08/934,139 (above)

Assignee: University of New Mexico [UNM]

Attorneys: See last page

Address: See last page

Senior Party

Inventors: Pramod K. Srivastava

Application: 09/090,754, filed 4 June 1998

Title: Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins

Priority 08/527,391, filed 13 September 1995
benefit: (5,837,251, issued 17 November 1998)

Assignee: Fordham University [Fordham]

Attorneys: See last page

Address: See last page

F. Counts and claims of the parties

Count 1

The method of UNM 332 claim 10 OR Fordham claim 62.

Count 3

The ADP-heat shock protein-peptide complex of UNM 716 claims 13, 19, OR 25.

Count 4²

The method of UNM 332 claim 22 OR Fordham claim 96.

The claims of the parties are:

Univ. of New Mexico 332: 1-23
716: 1-30
141: 1-18

Fordham Univ.: 60-69 and 71-96

² Substituted for Count 2 in Paper 98.

The claims corresponding to Count 1:

Univ. of New Mexico 332: 1, 3-5, and 7-12

Fordham Univ.: 60, 62-64, 78, 89, 90, and 92

The claims corresponding to Count 3:

Univ. of New Mexico 332: 13-30

141: 1-18

Fordham Univ.: 68, 69, 71-75, 82-88 and 96

The claims corresponding to Count 4:

Univ. of New Mexico 716: 13, 15-17, and 19-23

Fordham Univ.: 65-67, 79, 80, and 93-95

The claims not corresponding to any count:

Univ. of New Mexico 332: 2, 6, 14, and 18

716: 1-12

141: None

Fordham Univ.: 61, 76, 77, 79-81, and 91

G. Heading to be used on papers

Addendum 1 provides the heading that shall be used on all papers filed in the interference. See STANDING ORDER ¶ 3.5.

RICHARD TORCZON
Administrative Patent Judge

cc (electronic mail):

Paul Adams and Deborah Peacock of PEACOCK, MYERS & ADAMS P.C. for the University of New Mexico, and

Samuel B. Abrams and Michael J. Ryan of PENNIE & EDMONDS LLP for Fordham University (Antigenics, Inc., licensee).

Interference No. 104,761
Univ. of New Mexico v. Fordham Univ.

Paper 107
Page 8

ADDENDUM 1

Filed on behalf of: Party _____
By: Name of lead counsel
Name of backup counsel
Electronic mail addresses

Paper No. _____³

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
(Administrative Patent Judge Torczon)

UNIVERSITY OF NEW MEXICO
(5,747,332, 6,066,716, and 6,433,141),

Junior Party,

v.

FORDHAM UNIVERSITY
(09/090,754),

Senior Party.

Patent Interference No. 104,761

TITLE OF PAPER

³ Leave blank for the Board to insert the paper number when the paper is entered into the administrative record.

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

UNIVERSITY OF NEW MEXICO
(5,747,332, 6,066,716, and 6,433,141),

Junior Party,

v.

FORDHAM UNIVERSITY
(09/090,754),

Senior Party.

Interference No. 104,761

Before SCHAFER, TORCZON, and SPIEGEL, Administrative Patent Judges.

TORCZON, Administrative Patent Judge.

**DECISION ON RECONSIDERATION
and JUDGMENT**
(PURSUANT TO 37 CFR § 1.658)

INTRODUCTION

Following a decision on motions (Paper 98), the University of New Mexico [UNM] was placed under an order to show cause (Paper 99) why judgment should not be entered against UNM. The order to show cause noted that UNM, as junior party, failed to overcome Fordham's effective filing date. In the decision on motions, UNM's attack on Fordham's effective filing date also failed. The order to show cause also noted a pending Fordham motion to add another UNM patent to the interference.

In response, both parties have requested reconsideration of the decision on motions, UNM has responded to the order to show cause, and UNM has opposed

Fordham's motion to add another UNM patent. UNM is seeking reconsideration (Paper 100) of the decision to deny its Preliminary Motion 2, in which UNM argued that Fordham's claims would have been obvious to a person having ordinary skill in the art at the time of Fordham's invention. Fordham seeks reconsideration (Paper 102) of the decision to deny the part of its Preliminary Motion 4, in which Fordham argued that UNM's 716 claims 7-12 should correspond to count 3.

FINDINGS and CONCLUSIONS

Enumerated findings are supported by at least a preponderance of the evidence. The ultimate burden of proof for a motion lies with the movant. 37 C.F.R. § 1.637(a). The ultimate burden on priority lies with the junior party. 37 C.F.R. § 1.657(a). The burden on reconsideration lies with the requester. 37 C.F.R. §§ 1.640(c) and 1.658(b).

Reconsideration of UNM Preliminary Motion 2

- [1] UNM moved to have Fordham University's claims held unpatentable under 35 U.S.C. 103.
- [2] The motion cites the following references as the basis for unpatentability:

Palleros et al., "Hsp-70 Protein Complexes", 289 J. Biol. Chem. 13107 (1994) [2030]¹

Liberek et al., "Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK", 88 Proc. Nat'l Acad. Sci. 2874 (1991) [2031]

Liberek et al., "Escherichia coli DnaK Chaperone, the 70 kDa Heat Shock Protein Eukaryotic Equivalent, Changes Conformation upon ATP Hydrolysis, Thus Triggering Its Dissociation from a Bound Target Protein", 266 J. Biol. Chem. 14491 (1991) [2032]

¹ UNM exhibits are numbered from 2001; Fordham's, from 1001.

Welch et al., "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", 5 Mol. & Cell. Biol. 1229 (1985) [2033]

Lewis et al., "Involvement of ATP in the nuclear and nucleolar functions of the 70 kd heat shock protein", 4 EMBO J. 3137 (1985) [2035]

Bochner et al., "Escherichia coli DnaK protein possesses a 5'-nucleotidase activity that is inhibited by AppppA", 168 J. Bacteriol. 931 (1986) [2036]

Kassenbrock et al., "Interaction of heavy chain binding protein (BiP/GRP78) with adenine nucleotides" 8 EMBO J. 1461 (1989) [2037]

Skowyra et al., "The E. coli dnaK gene product, the hsp70 homolog, can reactivate heat-inactivated RNA polymerase in an ATP hydrolysis-dependent manner", 62 Cell 939 (1990) [2038]

Sadis et al., "Biochemical and biophysical comparison of bacterial DnaK and mammalian hsc73, two members of an ancient stress protein family", Curr. Res. in Prot. Chem. 339 (1990) [2039]

Flaherty et al., "Three-dimensional structure of the ATPase fragment of a 70K heat-shock cognate protein ", 346 Nature 623 (1990) [2040]

Sherman et al., "Formation in vitro of complexes between an abnormal fusion protein and heat shock proteins from Escherichia coli and yeast mitochondria", 173 J. Bacteriol. 7249 (1991) [2041]

Sadis et al., "Unfolded proteins stimulate molecular chaperone hsc70 ATPase by accelerating ADP/ATP exchange" 31 Biochem. 9406 (1992) [2042]

Richarme et al., "Specificity of the Escherichia coli chaperon DnaK (70-kDa heat shock protein) for hydrophobic amino acids", 268 J. Biol. Chem. 24074 (1993) [2043]

Blond-Elguindi et al., "Peptide-dependent stimulation of the ATPase activity of the molecular chaperone BiP is the result of conversion of oligomers to active monomers", 268 J. Biol. Chem. 12730 (1993) [2044]

[3] UNM also relied on the Welch declaration [2028], which cited the same papers.

[4] The decision on motions concluded:

The prior art UNM cited suggests that an ADP substrate could be substituted for the ATP substrate in the method of Welch 1985 if one seeks to isolate hsp-protein complexes. The motivation for the modification, however, hinges on the desirability of making hsp-protein complexes. "The mere fact that the prior art could be so modified would not have made the modification obvious unless the prior art suggested the desirability of the modification." In re Gordon, 733 F.2d 900, 902, 221 USPQ 1125, 1127 (Fed. Cir. 1984). Without a motivation to make such complexes, the fact that it could be done is academic. What motivation there is appears to come from the work of one of Fordham's inventors and was not cited by UNM against Fordham.

Moreover, it is not clear why a person having ordinary skill in the art would [have] expect[ed] the substitution to work. After all, Welch 1985 emphasized that its method isolated heat-shock proteins in their native form. Palleros, using a different method, found that adding ADP to (or substituting it for ATP in) the mobile phase of the chromatography system had the effect of stabilizing the complex much more than ATP alone. Assuming that a person having ordinary skill in the art had motivation to isolate hsp-protein complexes, the combined teachings of Welch 1985 and Palleros provide an experiment to try rather than a reasonable expectation of success. See In re Dow Chemical Co., 837 F.2d, 469, 473, 5 USPQ2d 1529, 1532 (Fed. Cir. 1985) (rejecting an "obvious to experiment" approach).

- [5] In requesting reconsideration of the decision, UNM cites two Fordham exhibits (Paper 100 at 11, citing Fordham exhibit 1019², and at 12, citing 1018³) and the characterization of the prior art in UNM's 332 patent [2066].
- [6] UNM stated its characterization of the prior art in its 332 patent as a material fact (UNM Prel. Mot. 2 at 4, Fact 2).
- [7] Fordham denied that characterization (Fordham Opp. 2 at 3).

² H. Udono & P.K. Srivastava, "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity", 178 J. Exp. Med. 1391 (1993).

³ N.E. Blachere et al., "Heat Shock Protein Vaccines Against Cancer", 14 J. Immunol. 352 (1993). Fordham's named inventor, Pramod K. Srivastava, is a co-author.

The UNM 332 patent is not prior art against Fordham's claims (except as a basis for a priority contest under 35 U.S.C. 102(g)(1)/135(a)). Moreover, while UNM's characterization of the prior art might be available as an admission against UNM, it is hardly evidence of unpatentability against Fordham.⁴

- [8] Neither of the Fordham exhibits now cited appear to have been cited in UNM's preliminary motion 2.
- [9] Both exhibits are 1993 journal articles that list the sole inventor named on Fordham's involved application, P.K. Srivastava, as a co-author.
- [10] UNM has not alleged that the papers in the Fordham exhibits were not available to UNM at the time it filed its motion.

It is axiomatic that the panel cannot have misapprehended or failed to appreciate an argument that was never made. Accord Rumsfeld v. Freedom NY, Inc., No. 02-1105, -1130, 2003 WL 22339495, at *1 (Fed. Cir. 2003) (Argument not raised in opening brief is waived for purposes of rehearing). Moreover, Fordham was not on notice of the basis now advanced for the unpatentability of its claims. Consequently, we do not have the benefit of Fordham's explanation of why its claims would be patentable despite these additional references. The alleged error in the decision on motions is our failure to enter what, in effect, would have been a new ground of rejection.

⁴ The Decision on Motions noted the apparent admission, but declined to hold UNM's claims unpatentable because the issue had not been developed in the motions process (Paper 98 at 47).

An administrative patent judge may exercise discretion to explore a new ground of rejection. 37 C.F.R. § 1.641. Moreover, the Board may exercise its discretion to recommend that an examiner explore the potential rejection, 37 C.F.R. § 1.659. Finally, we may simply decline to take any action at all.

We decline to proceed under § 1.641 at this late date on what might well prove to be a blind alley. Since Fordham is an applicant whose application will ultimately be remanded to an examiner, any remaining questions of unpatentability can be addressed in that forum.⁵ Cf. In re Hounsfield, 699 F.2d 1320, 1324, 216 USPQ 1045, 1048 (Fed. Cir. 1983) (refusing to entertain a late rejection but noting that the agency could explore it on remand). UNM has had its opportunity to make out a case for unpatentability.

The decision to deny UNM Preliminary Motion 2 has been reconsidered, but relief from that decision is DENIED.

Reconsideration of Fordham Preliminary Motion 4

[11] Fordham moved to have several additional UNM claims designated as corresponding to the counts, including having UNM 716 claims 7-12 designated as corresponding to count 3.

[12] The Board held (Paper 98 at 45):

As noted in the fact-finding, we do not consider the hsp110 family proteins of UNM 716 claim 7 to be anticipated by the hsp70 family proteins enumerated in UNM claims 13, 19, and 25. Moreover, claims 7-

⁵ We note that both of the Srivastava co-authored articles in question are listed as references on the front cover of the Fordham patent that issued from the parent application of Fordham's involved application. UNM has not suggested that the articles were not previously available to it.

12 are composition claims and are not stated in terms of a product-by-process. Consequently, Fordham's obviousness analysis must proceed from the obviousness of hsp110 family members from the enumerated hsp70 family members.

While the parties dispute whether the hsp110 family is part of the hsp70 family based on the degree of sequence and domain identity or similarity between hsp110 and DnaK, we are provided very little motivation for the substitution of an enumerated (in claims 13, 19, and 25) hsp70 family member with an hsp110 subfamily member, or with the modification of such an hsp70 family member into an hsp110 family member. In the context of UNM's disclosure, the only thing linking these heat-shock proteins is the fact that they (and members of other hsp families) may be purified in the same way. Since claim 7 is not a product-by-process claim, however, this process similarity does not help make out a case for obviousness. We cannot conclude that hsp110 complexes would have been obvious in view of other hsp70 complexes. If anything, the evidence suggests that a person having ordinary skill in the art would have expected hsp110 complexes to have been very different.

- [13] Fordham contends that the decision on motions applied the wrong standard for determining the separate patentability of the subject matter of UNM '716 claims 7-12 over the subject matter of count 3 (Paper 102 at 2-3):

In rejecting Fordham Preliminary Motion 4, the Board focused on the differences between hsp110 *per se* and *e.g.* DnaK *per se* (a representative hsp70 family member recited in Count 3) (Decision at page 45, first full paragraph). Instead, Fordham submits, the question of the patentable distinctness of UNM '716 claims 7-12 should have been established by determining whether the subject matter of the claims, *i.e.* ternary hsp110-ADP-peptide complexes, would have been obvious over the hsp70-ADP-peptide complexes recited in Count 3.

Although Fordham acknowledges that hsp110 and the hsp70 family members of Count 3 are different proteins, Fordham submits that the ternary hsp110-ADP-peptide complexes of UNM '716 claims 7-12 are obvious over *e.g.* the DnaK-ADP-peptide complexes of Count 3. More specifically, Fordham submits that in rendering the Decision concerning that part of Fordham Preliminary Motion 4 requesting that UNM '716 claims 7-12 be designated as corresponding to Count 3, the Board overlooked or misapprehended Fordham's argument that both hsp110 and *e.g.* DnaK have common functional domains providing the critical

biochemical traits, i.e. the ability to bind adenine nucleotides (ATP and ADP), and peptides or other proteins. In fact, the Board has concluded that "at the time of UNM's invention, the state of the art pointed to both protein-binding and ATP-binding for hsp110" (Decision, at page 42, first full paragraph, last sentence). Fordham submits that in rendering the Decision the Board has overlooked Fordham's arguments that, in view of e.g. DnaK-ADP-peptide ternary complexes of Count 3, it is obvious that hsp110, which is known to be able to bind ADP and a peptide separately, can also bind both simultaneously to provide the ternary complexes of UNM '716 claims 7-12 (see e.g. Fordham Preliminary Motion 4 at page 9; Fordham Reply Motion 4 at page 5, last two paragraphs extending onto page 6; and Fordham Reply Motion 4, at page 8, third full paragraph).

- [14] While the first paragraph of the cited portion of the Board decision does suggest that the obviousness of hsp110 in view of hsp70 is the issue under consideration, the second paragraph clarifies that in fact the Board considered the motivation for substituting hsp110 for hsp70 in the hsp70-ADP-peptide complex of count 3.

Fordham focuses on the fact that hsp110-peptide complexes can be formed in the same way that hsp70-peptide complexes are formed. The Board decision does not question the similarity of the process for forming such hsp-peptide complexes. Rather the decision focuses on the motivation for substituting hsp110 for hsp70 in the process. "The mere fact that the prior art could be so modified would not have made the modification obvious unless the prior art suggested the desirability of the modification." In re Gordon, 733 F.2d 900, 902, 221 USPQ 1125, 1127 (Fed. Cir. 1984). The Board decision found no such motivation and based its decision to deny on that lack of motivation. Moreover, there is no per se rule that similar complexes made the same way are thereby obvious in view of each other, thus side-stepping the question of motivation. Cf. TorPharm, Inc. v. Ranbaxy Pharm., Inc., 336 F.3d 1322, 1327, 67 USPQ2d 1511, 1514 (Fed. Cir. 2003) (confirming the absence of a per se rule of

unpatentability for products and methods of making such products). Fordham's request for reconsideration does not point to any overlooked motivation, so while the decision has been reconsidered, relief from the decision is DENIED.

UNM's opposition

- [15] The Board did not consider UNM's opposition (Paper 104) to Fordham's request in reaching its decision to deny Fordham relief.
- [16] Fordham had asked that the opposition be struck (Paper 105).

As discussed in Paper 105, an opposition to a request for reconsideration is not automatic under 37 C.F.R. § 1.640. That paper indicated that the opposition would be struck⁶ if it proved unnecessary. Consequently, UNM's opposition shall be STRUCK from the record.

JUDGMENT

Neither party has requested a final hearing (Paper 105). Consequently, this interference is ripe for final judgment. The addition of UNM 141 claims 1-18 (Paper 106) does not change this conclusion since the count to which they correspond has not changed and thus the priority case available to UNM to defend these claims has not changed.

ORDER

Upon consideration of Fordham's miscellaneous motion 4 and UNM's opposition, UNM's and Fordham's requests for reconsideration of the decision on motions, and

⁶ Paper 105 actually says "returned", but returning a paper makes little sense in an interference with electronic filing.

UNM's response to the order to show cause, and upon reconsideration of our decision on motions, it is:

ORDERED that relief from the decision denying UNM Preliminary Motion 2 be DENIED;

FURTHER ORDERED that relief from the decision denying Fordham Preliminary Motion 4 with regard to UNM 716 claims 7-12 be DENIED;

FURTHER ORDERED that the UNM opposition to Fordham's request for reconsideration be STRUCK from the record;

FURTHER ORDERED that judgment on priority as to Count 1 is awarded against UNM;

FURTHER ORDERED that UNM is not entitled to a patent containing claims 1, 3-5, and 7-12 of UNM's 5,747,332 patent, which correspond to Count 1;

FURTHER ORDERED that judgment on priority as to Count 3 is awarded against UNM;

FURTHER ORDERED that UNM is not entitled to a patent containing claims 13-30 of UNM's 6,066,716 patent or claims 1-18 of UNM's 6,433,141 patent, which correspond to Count 3;

FURTHER ORDERED that judgment on priority as to Count 4 is awarded against UNM;

FURTHER ORDERED that UNM is not entitled to a patent containing claims 13, 15-17, and 19-23 of UNM's 5,747,332 patent, which correspond to Count 4; and

FURTHER ORDERED that a copy of this decision be entered in the administrative record of UNM's 5,747,332 patent, 6,066,716 patent and 6,433,141 patent, and of Fordham's 09/090,754 application.

RICHARD E. SCHAFER
Administrative Patent Judge

RICHARD TORCZON
Administrative Patent Judge

CAROL A. SPIEGEL
Administrative Patent Judge

BOARD OF
PATENT
APPEALS AND
INTERFERENCES

INTERFERENCE
TRIAL SECTION

cc (electronic mail):

Paul Adams and Deborah Peacock of PEACOCK, MYERS & ADAMS P.C. for the University of New Mexico, and

Samuel B. Abrams and Michael J. Ryan of PENNIE & EDMONDS LLP for Fordham University (Antigenics, Inc., licensee).

Notice: Any agreement or understanding between parties to this interference, including any collateral agreements referred to therein, made in connection with or in contemplation of the termination of the interference, shall be in writing and a true copy thereof filed in the United States Patent and Trademark Office before termination of the interference as between said parties to the agreement or understanding. 35 U.S.C. 135(c); 37 C.F.R. § 1.661.